PPARγ agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats

European Journal of Pharmacology

Volumn 538, Issue 1-3, 2006, Pages 195-206

  Edgley, Amanda J ^a   Thalén, Pia G ^a   Dahllöf, Björn ^a   Lanne, Boel ^a   Ljung, Bengt ^a   Oakes, Nicholas D ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Cardiac hypertrophy; Fatty acid metabolism; PPAR

Indexed keywords

2 BROMOPALMITIC ACID; 3 [4 [2 (4 TERT BUTOXYCARBONYLAMINOPHENYL)ETHOXY]PHENYL] 2 ETHOXYPROPANOIC ACID; CARBON 14; DEOXYGLUCOSE; FAT; FATTY ACID; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLASMA PROTEIN; TRACER; TRIACYLGLYCEROL; TRITIUM; UNCLASSIFIED DRUG; X 334; 2-BROMOPALMITATE; 3 (4 (2 (4 TERT BUTOXYCARBONYLAMINOPHENYL)ETHOXY)PHENYL) (S) 2 ETHOXYPROPIONIC ACID; 3-(4-(2-(4-TERT-BUTOXYCARBONYLAMINOPHENYL)ETHOXY)PHENYL)-(S)-2-ETHOXYPROPIONIC ACID; CARBON; EPOXIDE; PALMITIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROPIONIC ACID DERIVATIVE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMEGALY; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG POTENCY; DRUG SELECTIVITY; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HEART LEFT VENTRICLE; HEART MUSCLE; HEART VENTRICLE; HYPOLIPEMIA; IN VIVO STUDY; INFUSION; INSULIN BLOOD LEVEL; LIPOLYSIS; MALE; NONHUMAN; PLASMA VOLUME; PRIORITY JOURNAL; RAT; RAT STRAIN; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ANIMAL; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; FAT INTAKE; METABOLISM; PATHOLOGY; TIME; WISTAR RAT;

ANIMALS; BLOOD PROTEINS; BODY WEIGHT; CARBON RADIOISOTOPES; CARDIOMEGALY; DEOXYGLUCOSE; DIETARY FATS; DIETARY SUPPLEMENTS; EPOXY COMPOUNDS; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HEART VENTRICLES; INSULIN; MALE; PALMITATES; PPAR GAMMA; PROPIONIC ACIDS; PROTEINS; RATS; RATS, WISTAR; TIME FACTORS; TRIGLYCERIDES; TRITIUM;

EID: 33747141166     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.03.058     Document Type: Article

References (47)

1. Antozzi C., and Zeviani M. Cardiomyopathies in disorders of oxidative metabolism. Cardiovasc. Res. 35 (1997) 184-199
2. Arakawa K., Ishihara T., Aoto M., Inamasu M., Kitamura K., and Saito A. An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin. Exp. Pharmacol. Physiol. 31 (2004) 8-13
3. Belke D.D., Betuing S., Tuttle M.J., Graveleau C., Young M.E., Pham M., Zhang D., Cooksey R.C., McClain D.A., Litwin S.E., Taegtmeyer H., Severson D., Kahn C.R., and Abel E.D. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 109 (2002) 629-639
4. Bell D., and McDermott B.J. Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy. Eur. J. Pharmacol. 508 (2005) 69-76
5. Benevolensky D., Belikova Y., Mohammadzadeh R., Trouve P., Marotte F., Russo-Marie F., Samuel J.L., and Charlemagne D. Expression and localization of the annexins II, V, and VI in myocardium from patients with end-stage heart failure. Lab. Invest. 80 (2000) 123-133
6. Berthiaume M., Sell H., Lalonde J., Gelinas Y., Tchernof A., Richard D., and Deshaies Y. Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. Am. J. Physiol., Regul. Integr. Comp. Physiol. 287 (2004) 1116-1123
7. Bressler R., and Goldman S. A role of fatty acid oxidation in cardiac hypertrophy. Cardioscience 4 (1993) 133-142
8. 2+ handling in the heart. Cardiovasc. Res. 65 (2005) 793-802
9. Coe N.R., and Bernlohr D.A. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim. Biophys. Acta 1391 (1998) 287-306
10. Duan S.Z., Ivashchenko C.Y., Russell M.W., Milstone D.S., and Mortensen R.M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ. Res. 97 (2005) 372-379
11. Eaton S., Bartlett K., and Pourfarzam M. Mammalian mitochondrial beta-oxidation. Biochem. J. 320 Pt 2 (1996) 345-357
12. Furler S.M., Cooney G.J., Hegarty B.D., Lim-Fraser M.Y., Kraegen E.W., and Oakes N.D. Local factors modulate tissue-specific NEFA utilization: assessment in rats using 3H-(R)-2-bromopalmitate. Diabetes 49 (2000) 1427-1433
13. Golfman L.S., Wilson C.R., Sharma S., Burgmaier M., Young M.E., Guthrie P.H., Van Arsdall M., Adrogue J.V., Brown K.K., and Taegtmeyer H. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am. J. Physiol. Endocrinol. Metab. 289 (2005) E328-E336
14. Gunteski-Hamblin A.M., Song G., Walsh R.A., Frenzke M., Boivin G.P., Dorn II G.W., Kaetzel M.A., Horseman N.D., and Dedman J.R. Annexin VI overexpression targeted to heart alters cardiomyocyte function in transgenic mice. Am. J. Physiol, Heart Circ. Physiol. 270 (1996) H1091-H1100
15. Hagenfeldt L. A gas chromatographic method for the determination of individual free fatty acids in plasma. Clin. Chim. Acta 13 (1966) 266-268
16. Hirayama H., Sugano M., Abe N., Yonemoch H., and Makino N. Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int. J. Cardiol. 77 (2001) 75-79
17. Holmang A., Yoshida N., Jennische E., Waldenstrom A., and Bjorntorp P. The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur. J. Clin. Investig. 26 (1996) 973-978
18. Jenkins A.B., Storlien L.H., Cooney G.J., Denyer G.S., Caterson I.D., and Kraegen E.W. Effects of blockade of fatty acid oxidation on whole body and tissue-specific glucose metabolism in rats. Am. J. Physiol: Endocrinol. Metab. 265 (1993) E592-E600
19. Kraegen E.W., James D.E., Jenkins A.B., and Chisholm D.J. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am. J. Physiol: Endocrinol. Metab. 248 (1985) E353-E362
20. Kusaka Y., Tanaka T., Okamoto F., Terasaki F., Matsunaga Y., Miyazaki H., and Kawamura K. Effect of sulfo-N-succinimidyl palmitate on the rat heart: myocardial long-chain fatty acid uptake and cardiac hypertrophy. J. Mol. Cell. Cardiol. 27 (1995) 1605-1612
21. Lanne B., Potthast F., Hoglund A., Brockenhuus von Lowenhielm H., Nystrom A.C., Nilsson F., and Dahllof B. Thiourea enhances mapping of the proteome from murine white adipose tissue. Proteomics 1 (2001) 819-828
22. Laplante M., Sell H., MacNaul K.L., Richard D., Berger J.P., and Deshaies Y. PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52 (2003) 291-299
23. Larsen P.J., Jensen P.B., Sorensen R.V., Larsen L.K., Vrang N., Wulff E.M., and Wassermann K. Differential influences of peroxisome proliferator-activated receptors gamma and-alpha on food intake and energy homeostasis. Diabetes 52 (2003) 2249-2259
24. Litwin S.E., Raya T.E., Gay R.G., Bedotto J.B., Bahl J.J., Anderson P.G., Goldman S., and Bressler R. Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction. Am. J. Physiol, Heart Circ. Physiol. 258 (1990) H51-H56
25. Matteo R.G., and Moravec C.S. Immunolocalization of annexins IV, V and VI in the failing and non-failing human heart. Cardiovasc. Res. 45 (2000) 961-970
26. Minoura H., Takeshita S., Ita M., Hirosumi J., Mabuchi M., Kawamura I., Nakajima S., Nakayama O., Kayakiri H., Oku T., Ohkubo-Suzuki A., Fukagawa M., Kojo H., Hanioka K., Yamasaki N., Imoto T., Kobayashi Y., and Mutoh S. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur. J. Pharmacol. 494 (2004) 273-281
27. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., and Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003) 2941-2948 (October 7, 2003)
28. Oakes N.D., and Furler S.M. Evaluation of free fatty acid metabolism in vivo. Ann. N. Y. Acad. Sci. 967 (2002) 158-175
29. Oakes N.D., Kjellstedt A., Forsberg G.B., Clementz T., Camejo G., Furler S.M., Kraegen E.W., Olwegard-Halvarsson M., Jenkins A.B., and Ljung B. Development and initial evaluation of a novel method for assessing tissue-specific plasma free fatty acid utilization in vivo using (R)-2-bromopalmitate tracer. J. Lipid Res. 40 (1999) 1155-1169
30. Oakes N.D., Thalen P.G., Jacinto S.M., and Ljung B. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50 (2001) 1158-1165
31. Odle J. New insights into the utilization of medium-chain triglycerides by the neonate: observations from a piglet model. J. Nutr. 127 (1997) 1061-1067
32. Panos T.C., and Finerty J.C. Effects of a fat-free diet on growing male rats with special reference to the endocrine system. J. Nutr. 54 (1954) 315-331
33. Pickavance L.C., Tadayyon M., Widdowson P.S., Buckingham R.E., and Wilding J.P. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br. J. Pharmacol. 128 (1999) 1570-1576
34. Randle P.J., Garland P.B., Hales C.N., and Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
35. Russell L.K., Finck B.N., and Kelly D.P. Mouse models of mitochondrial dysfunction and heart failure. J. Mol. Cell. Cardiol. 38 (2005) 81-91
36. Rustin P., Bourgeron T., Parfait B., Chretien D., Munnich A., and Rotig A. Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. Biochim. Biophys. Acta 1361 (1997) 185-197
37. Sack M.N., and Kelly D.P. The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Int. J. Mol. Med. 1 (1998) 17-24
38. Sack M.N., Rader T.A., Park S., Bastin J., McCune S.A., and Kelly D.P. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94 (1996) 2837-2842
39. Saudubray J.M., Martin D., de Lonlay P., Touati G., Poggi-Travert F., Bonnet D., Jouvet P., Boutron M., Slama A., Vianey-Saban C., Bonnefont J.P., Rabier D., Kamoun P., and Brivet M. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J. Inherit. Metab. Dis. 22 (1999) 488-502
40. Schiffrin E.L. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am. J. Physiol, Heart Circ. Physiol. 288 (2005) H1037-H1043
41. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., Staels B., and Auwerx J. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15 (1996) 5336-5348
42. Sidossis L.S., and Wolfe R.R. Glucose and insulin-induced inhibition of fatty acid oxidation: the glucose-fatty acid cycle reversed. Am. J. Physiol, Endocrinol. Metab. 270 (1996) E733-E738
43. Tang W.H., Francis G.S., Hoogwerf B.J., and Young J.B. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J. Am. Coll. Cardiol. 41 (2003) 1394-1398
44. Tso P., Karlstad M.D., Bistrian B.R., and DeMichele S.J. Intestinal digestion, absorption, and transport of structured triglycerides and cholesterol in rats. Am. J. Physiol.: Gastrointest. Liver Physiol. 268 (1995) G568-G577
45. Vasudevan A.R., and Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol. Ther. 6 (2004) 850-863
46. Yu X., Burgess S.C., Ge H., Wong K.K., Nassem R.H., Garry D.J., Sherry A.D., Malloy C.R., Berger J.P., and Li C. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1767-1772
47. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., Orci L., and Unger R.H. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1784-178 9